Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Denis C Talbot

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Theranostics|July 21, 2011
Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer PatientsAzeem Saleem, Julian C Matthews, Malcolm Ranson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2004
A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancerSrinivasan Madhusudan, Martin Foster, Sethupathi R Muthuramalingam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancerDenis C Talbot, Joachim von Pawel, Emma Cattell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanomaDavid J Propper, David Chao, Jeremy P Braybrooke, et al.
Nucleic Acids Research|August 23, 2005
Isolation of a small molecule inhibitor of DNA base excision repairSrinivasan Madhusudan, Fiona Smart, Paul Shrimpton, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2013
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052)Mary E R O'Brien, Rabab M Gaafar, Sanjay Popat, et al.
European Journal of Cancer (Oxford, England : 1990)|January 22, 2014
Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumoursTim Meyer, Wendi Qian, Martyn E Caplin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2010
Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose studyDenis C Talbot, Malcolm Ranson, Joanna Davies, et al.
Plos One|September 15, 2016
Targeted Next-Generation Sequencing of Plasma DNA from Cancer Patients: Factors Influencing Consistency with Tumour DNA and Prospective Investigation of Its Utility for DiagnosisPamela J Kaisaki, Anthony Cutts, Niko Popitsch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2005
Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanomaJeremy P Braybrooke, Andrew Slade, Gael Deplanque, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Theranostics|July 21, 2011
Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer PatientsAzeem Saleem, Julian C Matthews, Malcolm Ranson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2004
A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancerSrinivasan Madhusudan, Martin Foster, Sethupathi R Muthuramalingam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancerDenis C Talbot, Joachim von Pawel, Emma Cattell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2003
Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanomaDavid J Propper, David Chao, Jeremy P Braybrooke, et al.
Nucleic Acids Research|August 23, 2005
Isolation of a small molecule inhibitor of DNA base excision repairSrinivasan Madhusudan, Fiona Smart, Paul Shrimpton, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2013
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052)Mary E R O'Brien, Rabab M Gaafar, Sanjay Popat, et al.
European Journal of Cancer (Oxford, England : 1990)|January 22, 2014
Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumoursTim Meyer, Wendi Qian, Martyn E Caplin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2010
Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose studyDenis C Talbot, Malcolm Ranson, Joanna Davies, et al.
Plos One|September 15, 2016
Targeted Next-Generation Sequencing of Plasma DNA from Cancer Patients: Factors Influencing Consistency with Tumour DNA and Prospective Investigation of Its Utility for DiagnosisPamela J Kaisaki, Anthony Cutts, Niko Popitsch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2005
Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanomaJeremy P Braybrooke, Andrew Slade, Gael Deplanque, et al.
Pageof 3